Is There an Ozempic Lawsuit?
Yes. Individuals throughout the United States are pursuing Ozempic lawsuits after discovering that the weight loss drugs can cause stomach paralysis, gastric obstruction and other severe gastrointestinal side effects.
A growing body of medical research and adverse events reported to the U.S. Food and Drug Administration (FDA) have raised concern about the undisclosed side effects linked to semaglutide drugs.
Lawsuits allege that Novo Nordisk and its subsidiaries failed to adequately research the drugs and warn the medical community and patients about the risk of gastroparesis and other problems that may result from the diet drugs.
The product liability lawyers at Saiontz & Kirk, P.A. provide free consultations and claim evaluations for individuals diagnosed with side effects after taking Ozempic, Wegovy and other semaglutide drugs.
Which Semaglutide Drugs Will Be Named In Lawsuits?
Lawsuits are being reviewed against the manufacturers of Ozempic, Wegovy and Rybelsus weight loss and diabetes drugs over digestive and severe stomach problems.
Who Qualifies for an Ozempic Lawsuit?
Financial compensation may be available for individuals who received Ozempic or Wegovy injections, or took Rybelsus tablets, and suffered any of the following complications:
- Gastroparesis (Stomach Paralysis)
- Excessive vomiting
- Severe diarrhea
- Severe abdominal pain
- Gastrointestinal burning
- Gastric obstruction
- Gastroesophageal Reflux Disease (GERD)
- Other Gastrointestinal injuries
Our lawyers are also pursuing Mounjaro lawsuits for individuals who took tirzepatide and developed gastrointestinal injuries.
To help determine the Ozempic settlement amount that you or a loved one may be eligible to receive, request a no-obligation case evaluation today.
2023 Ozempic Lawsuit Update
Following recent studies and case reports linking Ozempic and gastrointestinal problems, individuals are now pursuing Ozempic lawsuits over the manufacturer’s failure to warn about the side effects of the GLP-1 receptor agonist drugs.
- August 2023 Update: The first of what is expected to be many Ozempic and Mounjaro lawsuits was filed over gastroparesis side effects in the U.S. District Court for the District of Louisiana on August 2, 2023.
- July 2023 Update: A CNN investigative report cautioned that a rising number of people are experiencing stomach paralysis after taking Ozempic and Wegovy. The report also emphasized the mounting evidence suggesting that the manufacturers of these diet drugs knew about the potential side effects.
- June 2023 Update: The American Society of Anesthesiologists (ASA) recommended that users temporarily discontinue Ozempic, Wegovy before elective surgery due to the risk of experiencing nausea and vomiting that could cause suffocation during anesthesia procedures.
Ozempic Lawsuit Settlements
As the Ozempic litigation remains in the early stages, there have not been any global Ozempic lawsuit settlements to date. However, our lawyers expect that as additional medical research is presented and potentially thousands of Ozempic gastrointestinal injury lawsuits are filed by users throughout the United States, the manufacturers could decide to settle the claims to avoid a lengthy litigation.
How much is an Ozempic settlement payout worth?
The compensation you could recover in an Ozempic gastroparesis lawsuit will vary depending on the extent of the injuries sustained. The impact of gastroparesis from Ozempic can result in very different consequences, with some users requiring prolonged hospitalization and being left with permanent disabilities. The individual circumstances in each case will be considered in negotiating any Ozempic settlement.
How is an Ozempic lawsuit settlement calculated?
Similar to other pharmaceutical drug and product liability lawsuits resulting in personal injuries to users, multiple factors will be considered when established an Ozempic lawsuit settlement amount, including;
- Extent of the Injury: The gravity and enduring nature of the gastrointestinal injury experienced by the plaintiff will play a pivotal role in shaping the compensation amount. Low or mild discomfort would likely result in a lesser settlement figure compared to a persistent injury or disability.
- Medical Expenses: Costs related to the injury, such as hospitalization, prescribed medications, surgeries, and follow-up treatments, will be a significant determinant in the settlement amount.
- Future Medical Needs: Predicted medical expenses, especially if the injury might require ongoing treatments, will also be evaluated when considering the settlement.
- Lost Wages: If the injury resulted in the plaintiff missing work or becoming unable to work either temporarily or permanently, these lost earnings will be accounted for in the settlement calculation..
- Pain and Suffering: This encompasses both the physical pain and emotional turmoil undergone by the individual due to the injury.
- Strength of Evidence: How compelling and credible the evidence is in establishing a link between Ozempic and the gastrointestinal injuries will be paramount. A stronger case may push the manufacturer towards a larger settlement.
To find out how much your potential Ozempic lawsuit settlement could be worth, contact our lawyers for a free consultation to discuss the specifics of your case.
Problems With Ozempic, Wegovy and Rybelsus
Semaglutide, or better known as Ozempic, is a prescription medication that was formulated by Novo Nordisk and received FDA’s approval for the treatment of type 2 diabetes on December 5, 2017. The drug is a once-weekly injectable GLP-1 receptor agonist designed to regulate blood sugar by enhancing insulin production.
Shortly after the drug was released on the market it became extremely popular for its ability to help with weight loss. Ozempic has been shown to help some lose weight by its ability to mimic the GLP-1 hormone that is released from the intestines after eating. This causes insulin release, slows gastric emptying, and suppresses secretion of glucagon (a hormone that increases blood sugar).
By mimicking GLP-1’s action, Ozempic can slow the movement of food through the stomach, which may help users feel full longer, reduces appetite and leads to caloric excretion.
With Ozempic quickly becoming a top selling drug due to off label prescriptions as an obesity medicine, the manufacturer subsequently released an oral version of semaglutide in a tablet for the treatment of Type 2 diabetes named Rybelsus, which was approved by the FDA in 2019.
While the drug maker has made claims that it released the diabetes medications in a tablet form to accommodate those who cannot tolerate Ozempic injections, many critics have claimed the Rybelsus tablet was released in an effort to make the drug more affordable and boost appeal to the masses seeking semaglutide as an obesity treatment.
Recognizing the demand for the diabetes drug Ozempic among individuals seeking off label weight loss benefits, Novo Nordisk introduced another variant of semaglutide called Wegovy. In June 2021, the FDA approved Wegovy as a weight loss medication for adults battling obesity and those overweight due to specific health issues.
Ozempic’s success for obesity treatment prompted other drug makers to formulate their own version of GLP-1 receptor agonists. By May 2022, Eli Lilly had developed and received approval for its drug tirzepatide, which was branded as Mounjaro.
However, as millions of individuals have turned to semaglutide and tirzepatide for weight reduction, a surge of adverse event reports involving users developing severe gastrointestinal issues after taking Ozempic, Wegovy, Rybelsus and Mounjaro have been reported.
Ozempic Side Effects Reported to the FDA
Individuals are claiming that Novo Nordisk and its subsidiaries put profits before its customers’ safety by ignoring the growing number of side effects that were reported to the FDA by individuals taking Ozempic, Wegovy and Rybelsus.
According to the FDA’s FAERS database, the number of adverse reactions each year since Ozempic, Rybelsus and Wegovy were released have climbed significantly, reaching a total of 18,846 adverse events as of June 30, 2023.
The number of Ozempic side effects reported per year are as follows;
- 2018 Adverse Events: 1,059
- 2019 Adverse Events: 1,246
- 2020 Adverse Events: 2,781
- 2021 Adverse Events: 4,001
- 2022 Adverse Events: 5,851
- 2023 Adverse Events: (As of June 30, 2023) 3,908
According to the FDA’s database, the number of adverse events reported for each semaglutide drug since they have been released up until June 30, 2023, are as follows;
- Ozempic adverse events: 14,149
- Rybelsus adverse events: 2,540
- Wegovy adverse events: 2,201
Many of the Ozempic side effects reported to the FDA have included gastrointestinal problems, including;
- Nausea: 3,590
- Severe Vomiting: 2,031
- Pancreatitis: 607
- Abdominal Distension: 555
- Abdominal Pain: 548
- Abdominal/Stomach Pain: 512
- Gastroesophageal Reflux Disease: 274
- Gastrointestinal Disorder: 240
- Acute Kidney Injury: 196
- Cholelithiasis: 119
- Renal Failure: 92
- Impaired Gastric Emptying: 82
- Gastric Disorder: 65
- Gastritis: 60
- Gallbladder Disorder: 48
- Gastroenteritis: 31
Ozempic Warning Label Failures
Despite thousands of adverse reactions being reported by individuals taking Ozempic within the first two years, the manufacturer failed to issue adequate warnings. In March 2022, the Ozempic label was updated to add information about gallbladder disease risks. However, it continues to inaccurately disclose the full extent of problems experienced by users.
As of late 2023, the manufacturer has yet to issue any patient safety update or issue an Ozempic recall regarding potential gastroparesis side effects that users have experienced. The current drug label continues to minimize the potential Ozempic gastrointestinal problems being reported by users, and the manufacturer continues to aggressively market use of the drug as a weight loss treatment.
Rather than further investigating the nearly 20,000 adverse events reported to the FDA, Novo Nordisk pumped billions into advertising and celebrity endorsers speaking out on the weight loss benefits, producing billions of dollars in revenue while users continue to report new digestive illnesses.
Ozempic and Gastroparesis
Individuals are now filing lawsuits against the makers of Ozempic claiming that the manufacturer was well aware of reports of gastric disorders and symptoms that align with the onset of severe gastroparesis, yet failed to further investigate the severity or permanency of the injury risks.
Stomach Paralysis From Ozempic
Gastroparesis arises when the stomach muscles malfunction, inhibiting their ability to adequately process and move food. This impedes the stomach from efficiently emptying itself.
Ozempic is intentionally designed to slow gastric emptying to aid in weight loss. As a result, lawsuits are claiming the manufacturer failed to warn that the continuous use of Ozempic and Wegovy can cause some individuals to experience prolonged and chronic delays in stomach emptying.
Symptoms of Gastroparesis from Ozempic may include;
- Feeling full quickly when eating
- Abdominal bloating
- Stomach pain
Ozempic & Wegovy Clinical Trials Show Symptoms of Gastroparesis
Lawsuits allege the drug maker was aware of the risk of stomach paralysis injuries during clinical trials, yet failed to update warning labels or adequately warn users and the medical community.
During Ozempic clinical trials, 20% of participants experienced nausea, and 10% noted occurrences of vomiting, which are both symptoms prevalent in cases of gastroparesis.
During Wegovy clinical trials, close to 44% of Wegovy users experienced nausea and nearly 25% of the test subjects also reported incidents of vomiting.
The heightened occurrences of nausea and vomiting incidents found in the Wegovy trial align with the theory that semaglutide causes an increased risk of gastroparesis, since Wegovy is more than double the dose at 2.4mg compared to Ozempic’s 1mg dose. However, individuals using Ozempic for weight loss typically receive the higher doses of semaglutide similar to what is contained in Wegovy.
Ozempic Delays Gastric Emptying Warning
In July 2023, the American Society of Anesthesiologists (ASA) spotlighted the potential hazards linked to a condition called delayed gastric emptying from Ozempic and Wegovy, particularly for users undergoing surgical procedures. Due to side effects like nausea and vomiting from Ozempic, patients might face heightened risks of choking or inhaling food into the respiratory system while under general anesthesia or deep sedation.
This caution regarding Wegovy and Ozempic was part of broader ASA recommendations, issued in light of the medications’ increasing popularity as weight management solutions. The guidelines suggest daily users of drugs like Ozempic or Wegovy refrain from taking them on the day of surgery. Those on a weekly regimen should discontinue their use one week prior to the surgical procedure. It’s also recommended that patients liaise with an endocrinologist during this medication pause to ensure effective diabetes management.
Furthermore, the guidelines advise medical professionals to think about postponing surgeries if the patient reports significant gastrointestinal symptoms on the day of the procedure, such as pronounced nausea, vomiting, abdominal discomfort, or bloating.
Ozempic Gallbladder Injuries and Side Effects
Research indicates a connection between Ozempic and severe gastrointestinal events, specifically gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis).
In 2017, the journal Diabetes, Obesity & Metabolism published a pivotal meta-analysis examining the effects of Ozempic on pancreatitis and gallbladder disease. This research was the first to link Ozempic with an increased risk of gallbladder diseases including gallstones and gallbladder inflammation due to delayed gastric emptying.
When the gallbladder doesn’t regularly or fully empty, bile can accumulate, potentially raising the risk of gallstone formation. These gallstones can then obstruct the bile ducts, leading to inflammation or infection, possibly necessitating gallbladder removal.
Typically, gallbladder disease symptoms manifest as intense pain in the upper right or center of the abdomen. This pain might be constant or come and go, and it can be paired with intense stomach discomfort, nausea, vomiting, and fever.
At this time, our lawyers are not reviewing Ozempic gallbladder injury cases.
Allegations Raised In Ozempic Lawsuits
Individuals throughout the United States are currently pursuing Ozempic lawsuits against Novo Nordisk and its subsidiaries raising allegations that the manufacturer,
- Failed to adequately research the link between semaglutide and stomach problems
- Failed to warn about the increased risk of gastrointestinal side effects
- Falsely advertised the medications as a safe weight loss drug.
- Failed to issue an Ozempic recall to ensure consumers were aware of the health risks.
Are there any costs to hire a lawyer for my Ozempic case?
There are absolutely no out-of-pocket costs to review your case or hire our attorneys. Ozempic lawsuits are evaluated for individuals throughout the United States, and all cases are handled on a contingency fee basis.
Through the use of contingency attorney fees, individuals have access to the experience and resources of our national law firm for their Ozempic, Wegovy or Rybelsus lawsuit — regardless of their individual financial resources.
You pay nothing up front to hire our Ozempic lawyers, and we only receive an attorney fee or expenses out of the money that is obtained from the manufacturer. Our law firm receives nothing unless we win your case!
What are the steps in an Ozempic case evaluation?
Complete Our Case Evaluation Request Form. Providing contact information and some information about your Ozempic problems.
Get Contacted by Saiontz & Kirk, P.A. You will be contacted by our law firm to help determine if financial compensation may be available for you and your family.
You Decide If You Want to Move Forward. If our lawyers determine that we can help with your case then you decide whether to move forward and hire us to pursue compensation.